Rhumbline Advisers Neurocrine Biosciences Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rhumbline Advisers holds 321,747 shares of NBIX stock, worth $37.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
321,747
Previous 324,288 0.78%
Holding current value
$37.8 Million
Previous $44.6 Million 17.03%
% of portfolio
0.03%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$114.58 - $153.15 $291,147 - $389,154
-2,541 Reduced 0.78%
321,747 $37 Million
Q2 2024

Aug 01, 2024
BUY
$130.86 - $143.19 $285,405 - $312,297
2,181 Added 0.68%
324,288 $44.6 Million
Q1 2024

May 09, 2024
BUY
$130.4 - $143.74 $415,584 - $458,099
3,187 Added 1.0%
322,107 $44.4 Million
Q4 2023

Feb 08, 2024
SELL
$106.07 - $132.76 $699,319 - $875,286
-6,593 Reduced 2.03%
318,920 $42 Million
Q3 2023

Nov 09, 2023
SELL
$94.02 - $117.1 $262,691 - $327,177
-2,794 Reduced 0.85%
325,513 $36.6 Million
Q2 2023

Aug 08, 2023
BUY
$89.53 - $104.87 $1.94 Million - $2.28 Million
21,713 Added 7.08%
328,307 $31 Million
Q1 2023

May 11, 2023
BUY
$94.11 - $123.02 $620,749 - $811,439
6,596 Added 2.2%
306,594 $31 Million
Q4 2022

Feb 14, 2023
BUY
$106.72 - $127.06 $1.34 Million - $1.59 Million
12,548 Added 4.37%
299,998 $35.8 Million
Q3 2022

Nov 10, 2022
BUY
$92.03 - $107.81 $829,650 - $971,907
9,015 Added 3.24%
287,450 $30.5 Million
Q2 2022

Aug 11, 2022
BUY
$75.79 - $100.07 $1.76 Million - $2.32 Million
23,171 Added 9.08%
278,435 $27.1 Million
Q1 2022

May 12, 2022
BUY
$72.45 - $94.81 $26,371 - $34,510
364 Added 0.14%
255,264 $23.9 Million
Q4 2021

Feb 10, 2022
BUY
$79.65 - $106.22 $305,617 - $407,566
3,837 Added 1.53%
254,900 $21.7 Million
Q3 2021

Nov 12, 2021
SELL
$86.18 - $99.03 $79,802 - $91,701
-926 Reduced 0.37%
251,063 $24.1 Million
Q2 2021

Aug 05, 2021
SELL
$89.43 - $102.27 $194,241 - $222,130
-2,172 Reduced 0.85%
251,989 $24.5 Million
Q1 2021

May 06, 2021
BUY
$87.57 - $119.4 $12.3 Million - $16.8 Million
140,532 Added 123.68%
254,161 $24.7 Million
Q4 2020

Feb 10, 2021
SELL
$86.91 - $108.33 $547,533 - $682,479
-6,300 Reduced 5.25%
113,629 $10.9 Million
Q3 2020

Nov 12, 2020
SELL
$96.16 - $135.15 $755,048 - $1.06 Million
-7,852 Reduced 6.14%
119,929 $11.5 Million
Q2 2020

Aug 13, 2020
BUY
$85.09 - $130.36 $2.32 Million - $3.56 Million
27,323 Added 27.2%
127,781 $15.6 Million
Q1 2020

May 06, 2020
BUY
$75.11 - $113.76 $7,435 - $11,262
99 Added 0.1%
100,458 $8.7 Million
Q4 2019

Feb 05, 2020
BUY
$86.8 - $118.57 $229,933 - $314,091
2,649 Added 2.71%
100,359 $10.8 Million
Q3 2019

Oct 23, 2019
SELL
$83.82 - $101.5 $36,126 - $43,746
-431 Reduced 0.44%
97,710 $8.81 Million
Q2 2019

Aug 14, 2019
BUY
$72.24 - $91.27 $43,344 - $54,762
600 Added 0.62%
98,141 $8.29 Million
Q1 2019

May 01, 2019
BUY
$69.31 - $91.53 $14,139 - $18,672
204 Added 0.21%
97,541 $8.59 Million
Q4 2018

Jan 31, 2019
SELL
$68.32 - $124.36 $294,869 - $536,737
-4,316 Reduced 4.25%
97,337 $6.95 Million
Q3 2018

Nov 07, 2018
SELL
$98.88 - $125.85 $199,440 - $253,839
-2,017 Reduced 1.95%
101,653 $12.5 Million
Q2 2018

Aug 06, 2018
BUY
$75.3 - $105.99 $144,199 - $202,970
1,915 Added 1.88%
103,670 $10.2 Million
Q1 2018

May 02, 2018
SELL
$75.88 - $92.43 $232,723 - $283,482
-3,067 Reduced 2.93%
101,755 $8.44 Million
Q4 2017

Feb 09, 2018
SELL
$58.53 - $77.59 $43,253 - $57,339
-739 Reduced 0.7%
104,822 $8.13 Million
Q3 2017

Nov 06, 2017
BUY
$47.97 - $61.28 $5.06 Million - $6.47 Million
105,561
105,561 $6.47 Million

Others Institutions Holding NBIX

# of Institutions
623
Shares Held
94.2M
Call Options Held
632K
Put Options Held
621K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email